PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Having expanded its top line through CDAO and cosmetics revenue, Tiumbio now faces a key test of whether clinical data for endometriosis drug merigolix and immuno-oncology candidate tosposertib can translate into a licensing deal this year.
2025 consolidated revenue rose sharply year over year to KRW 12.29 billion, with the CDAO and natural cosmetics businesses building a steadier revenue base
Immuno-oncology candidate tosposertib disclosed a 75% response rate and 10.9-month median progression-free survival in first-line head and neck cancer at ASCO 2026
Management has set a goal of concluding at least one additional licensing deal this year, centered on endometriosis drug merigolix
Double-digit-billion-won operating losses and negative operating cash flow have persisted for four consecutive years
A prior licensing deal for a respiratory indication with Chiesi was terminated with rights returned, underscoring the need to verify partnering execution
Founded in 2016, Tiumbio develops treatments for rare and intractable diseases while also running a Contract Development and Analysis Organization (CDAO) business and a natural cosmetics line to build a steadier revenue base.
The CDAO business, which provides pharmaceutical process development and protein analysis services, posted 2025 revenue of KRW 7.4 billion, up 8.7% year over year, while a newly added natural cosmetics line generated KRW 4.9 billion in the same year.
The core drug pipeline centers on merigolix (TU2670), a treatment for endometriosis and uterine fibroids licensed out to Daewon Pharmaceutical in Korea and Hansoh Pharmaceutical in China, with rights to the United States, Europe and other major regions still retained.
A domestic Phase 2 trial for the uterine fibroid indication is being run by Daewon Pharmaceutical, while a European Phase 2a trial for endometriosis has already generated results.
Immuno-oncology candidate tosposertib (TU2218), a dual inhibitor of TGF-β and VEGF, is in a Phase 2 trial combined with Merck's Keytruda for head and neck and biliary tract cancers, with Keytruda supplied free of charge by Merck.
A prior licensing deal for a respiratory indication, NCE401, with Italy's Chiesi was terminated after Chiesi notified the company of a return of rights.
In the head and neck cancer space, competing candidates with similar mechanisms include Bicara Therapeutics' ficerafusp alfa and Merus's petosemtamab, against which tosposertib's data are being compared.
The company has a track record of three licensing deals with Daewon Pharmaceutical, Hansoh Pharmaceutical and Chiesi, and has positioned proving commercial outcomes on the strength of clinical evidence as its core business-development objective.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩2.6B | -₩3.5B | −133.7% |
| 2025Q3 | ₩3.1B | -₩4.5B | −144.8% |
| 2025Q4 | ₩4.4B | -₩2.8B | −62.6% |
| 2026Q1 | ₩3B | -₩4.5B | −153.8% |
| 2026Q2 | ₩4.5B | -₩4.2B | −94.8% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩9.1B | -₩25.6B | -₩31.4B | −281.2% | −51.4% | 54.5% |
| 2023 | ₩4.9B | -₩27.8B | -₩19B | −568.1% | −27.2% | 69.9% |
| 2024 | ₩6.8B | -₩18.7B | -₩23.5B | −275.3% | −44.9% | 111.4% |
| 2025 | ₩12.3B | -₩16.1B | -₩18.8B | −131.4% | −46.0% | 161.1% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
2025 consolidated revenue reached KRW 12.29 billion, up sharply from KRW 6.79 billion in 2024, marking a rebound after revenue had declined from KRW 9.12 billion in 2022 to KRW 4.90 billion in 2023.
Operating loss narrowed to KRW 16.15 billion in 2025 from KRW 18.70 billion in 2024 and KRW 27.83 billion in 2023, showing a moderating trend in loss size. The operating margin also improved to -131.4% in 2025 from -275.3% in 2024 and -568.1% in 2023.
Net loss attributable to owners narrowed to KRW 18.79 billion in 2025 from KRW 23.55 billion in 2024, though the improvement has not been consistent every year when compared with KRW 31.40 billion in 2022 and KRW 19.04 billion in 2023.
On a quarterly basis, the loss widened in the third quarter of 2025 with revenue of KRW 3.12 billion and an operating loss of KRW 4.52 billion, then narrowed in the fourth quarter to revenue of KRW 4.45 billion and an operating loss of KRW 2.79 billion, before widening again in the first quarter of 2026 to revenue of KRW 2.95 billion and an operating loss of KRW 4.54 billion, and then posting revenue of KRW 4.48 billion and an operating loss of KRW 4.24 billion in the second quarter, illustrating substantial quarter-to-quarter volatility.
Over the trailing four quarters from the third quarter of 2025 through the second quarter of 2026, the cumulative net loss attributable to owners totaled KRW 18.40 billion, reflecting the simultaneous progress of continued drug-development spending and expanding CDAO and cosmetics revenue.
Operating cash flow has recorded a net outflow every year from 2022 through 2025, ranging from roughly negative KRW 16 billion to negative KRW 20.6 billion, indicating that revenue alone has not been sufficient to cover research and development spending.
The debt ratio rose sharply from 54.5% in 2022 to 161.1% in 2025, reflecting both the erosion of equity from accumulated losses and the effects of external fundraising.
The global endometriosis treatment market is projected by GlobalData to grow to roughly USD 2.8 billion by 2029, forming the backdrop for interest in the commercialization potential of oral GnRH antagonist drugs such as merigolix.
Head and neck cancer remains an area of significant unmet need, as the first-line response rate for existing immuno-oncology monotherapy stays around 20%, and even chemotherapy combinations only reach about 36% with substantial added toxicity, sustaining demand for new treatment options.
In this space, Bicara Therapeutics in the United States and Merus in the Netherlands are competing with similarly dual-mechanism TGF-β/EGFR-related candidates, disclosing data at the same conferences, which naturally invites market comparisons of efficacy and safety.
Across Korea's broader biotech sector, attention is shifting from establishing clinical evidence toward proving commercial viability through actual licensing deals, and DB Securities assessed in a March 2026 report that Tiumbio has proven its technological capability through clinical trials and must now prove its commercial viability through contracts.
The revenue-requirement issue common to KOSDAQ technology-listed companies has also drawn industry attention, and Tiumbio has addressed this by expanding its consolidated revenue base through the CDAO and cosmetics businesses.
Relative to peers, the company's multiple licensing track record in endometriosis and uterine fibroids, combined with global-conference data disclosures in immuno-oncology, are cited as key factors in its partnering negotiating position.
Tiumbio has designated 2026 as the commercialization year for its clinical-stage pipeline, setting a company-wide goal of releasing additional research data and pursuing licensing deals.
In May 2026, tosposertib disclosed a 75% response rate and a median progression-free survival of 10.9 months in the first-line head and neck cancer patient group at ASCO, and the company stated it plans to swiftly pursue an FDA Breakthrough Therapy Designation application and advance global partnership discussions on this basis.
For merigolix, the company is discussing further global licensing for the remaining U.S. and European rights following the domestic and Chinese deals, with vice president and CFO Ko Hyun-sil stating in an April 2026 interview that the goal is to close at least one licensing deal this year, while prioritizing deal quality and partner fit over closing speed.
The company has also stated that it engaged Yale University's Hugh S. Taylor, an authority in endometriosis, as a scientific advisor for merigolix's global clinical and business-development strategy.
On the funding side, CFO Ko noted that standalone cash and cash equivalents stood at around KRW 17 billion at the end of 2025, with annual cash burn of about KRW 13 billion.
The CDAO and cosmetics businesses are expected to continue supporting the revenue base, while the accumulation of clinical data and the outcome of licensing negotiations for the drug pipeline will likely be the key variables shaping future earnings and financial structure.
The current share price trades at a level reflecting a substantial premium over net asset value, suggesting that expectations around pipeline progress and potential licensing deals are already partly priced into the market capitalization.
With losses continuing, the price-to-earnings ratio is not calculable in the conventional sense, a feature common to many clinical-stage biotech companies. No dividend is being paid, so there is no dividend-yield appeal in this stock, similar to peer clinical-stage biotech companies.
Over the past several years, the share price has shown large swings tied to clinical data readouts and licensing-related news, indicating that pipeline events tend to have a greater influence on valuation than reported earnings.
Should upfront or milestone payments from a licensing deal materialize, the financial structure and valuation calculus could shift accordingly.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Tosposertib presented a 75% response rate and 10.9-month median progression-free survival in first-line head and neck cancer at ASCO 2026, an improvement over existing standard-of-care figures. The company stated it plans to pursue an FDA Breakthrough Therapy Designation application based on this data.
However, the patient population evaluated remains limited, making the extension to longer-term durability data a key point to watch.
2025 consolidated revenue rose sharply year over year with the addition of the CDAO and new cosmetics businesses, while operating losses narrowed compared with 2023 and 2024. This could help ease the pace of cash burn needed to fund drug research.
It should be noted, however, that revenue expansion does not substitute for the fundamental value of the endometriosis and oncology pipelines.
Tiumbio has a track record of three licensing deals with Daewon Pharmaceutical, Hansoh Pharmaceutical, and Chiesi, and merigolix retains room for further deals covering remaining rights in the United States, Europe, and other regions.
Management has set a goal of closing at least one additional licensing deal this year. However, negotiation terms and timing have not been disclosed, so the actual outcome and scale remain to be confirmed.
Operating losses in the double-digit billions of won have continued for four consecutive years from 2022 through 2025, and operating cash flow has posted a net outflow every year. The debt ratio rose sharply from 54.5% in 2022 to 161.1% in 2025. If inflows from licensing deals are delayed, the need for additional fundraising could grow.
A prior licensing deal for a respiratory indication, NCE401, with Italy's Chiesi was terminated after the partner notified Tiumbio of a return of rights. This illustrates that signing a deal does not guarantee eventual commercial success.
Additional partnering for merigolix and tosposertib could similarly see terms or timing delayed or altered during negotiations.
In the first-line head and neck cancer market, similarly dual-mechanism candidates from Bicara Therapeutics in the United States and Merus in the Netherlands have already reported response rates in the 50-60% range and continue to disclose data at conferences.
While tosposertib's early response rate has appeared relatively high, demonstrating an edge in longer-term measures such as duration of response and overall survival will be necessary to complete the case for commercial competitiveness. With only around two dozen patients evaluated so far, further data expansion is needed.
Tosposertib's early response-rate data are based on a limited number of evaluable patients, and figures could shift as the patient population grows and follow-up periods lengthen.
The outcome of an FDA Breakthrough Therapy Designation application and reviews by regulators in various countries are also difficult to predict. Merigolix similarly must go through separate clinical and approval processes for the uterine fibroid and endometriosis indications.
With net losses and negative operating cash flow continuing for four straight years and the debt ratio rising, the possibility of further equity dilution through rights offerings or convertible bond issuance cannot be ruled out.
Indeed, recent additional listing disclosures have followed conversions of privately placed domestic convertible bonds. If upfront payments from licensing deals do not materialize as quickly as hoped, funding pressure could intensify.
If management's stated goal of at least one licensing deal this year is delayed or the terms fall short of market expectations, share price volatility could increase.
As with the prior NCE401 deal with Chiesi that ended with a return of rights, there remains a standing risk that even signed deals could be terminated early.
Because the company's strategy prioritizes partners' commercialization commitment over deal speed, the timing of any deal closing could also come later than the market anticipates.
Check the third-quarter report for how the CDAO and cosmetics revenue mix and loss trend have changed from the prior quarter.
Confirm whether management's stated goal of at least one licensing deal this year is achieved, and review the deal terms including partner, territory, and contract size.
Monitor how the outcome of tosposertib's FDA Breakthrough Therapy Designation application affects the pace of partnership discussions and valuation.
The company's presentation at this conference can provide a read on concrete progress in global partnering discussions.
Tiumbio is expanding its revenue base through the CDAO and cosmetics businesses while simultaneously advancing clinical data disclosures and licensing discussions for its two core pipelines, merigolix and tosposertib. 2025 revenue surpassed KRW 10 billion for the first time and operating losses showed a narrowing trend, yet the financial structure marked by four consecutive years of net losses and negative operating cash flow remains a burden.
Tosposertib unveiled improved response rate and survival data at ASCO 2026 and signaled plans to pursue FDA Breakthrough Therapy Designation, while additional licensing for merigolix's remaining rights beyond the existing Korean and Chinese deals has been set as management's top priority.
However, as illustrated by the earlier return of rights under the NCE401 deal, signing a license is a separate matter from sustaining one, and demonstrating commercial competitiveness against rival candidates in head and neck cancer remains a key hurdle.
The direction of future earnings and valuation will likely hinge heavily on whether a licensing deal is closed this year, the credibility of further clinical data, and the specifics of any funding plans.
Readers should weigh these business-development, clinical, and financial factors comprehensively in forming their own judgment.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.